Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson's Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Vipadenant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Biogen
- 25 May 2007 New trial record.